PuraPharm (HKSE:01498) Short Percentage of Float

View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of PuraPharm's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PuraPharm's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where PuraPharm's Short Percentage of Float falls into.

PuraPharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Short Percentage of Float

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.

Executives

Chan Yu Ling, Abraham	2101 Beneficial owner
Man Yee Wai, Viola	2202 Interest of your spouse
Fullgold Development Limited	2101 Beneficial owner

PuraPharm Headlines

No Headlines